United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

sHLA-G ELISA

sHLA-G ELISA
  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:soluble HLA-G
  • Species:Human
United States orders are shipped from our US branch, BioVendor, LLC
Cat. No. Size Price


RD194070100R 96 wells (1 kit) $795
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Plasma-EDTA, Amniotic fluid, Cell culture supernatant

Sample Requirements

25 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

3.91–125 Units/ml

Limit of Detection

0.6 Units/ml

Intra-assay (Within-Run)

n = 8; CV = 4.2%

Inter-assay (Run-to-Run)

n = 11; CV = 7.0%

Spiking Recovery

91,20%

Dilution Linearity

99,40%

Summary

Features

  • It is intended for research use only
  • The total assay time is about 20 hours
  • The kit measures shedded HLA-G1 and HLA-G5 in EDTA plasma, amniotic fluid, or cell culture supernatant
  • Calibrator is human native protein
  • Assay format is 96 wells
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Immune Response, Infection and Inflammation, Reproduction, Transplantation

Summary

HLA-G differs from the other MHC class I genes by its low polymorphism and alternative splicing that generates seven HLA-G proteins, whose tissue-distribution is restricted to normal fetal and adult tissues that display a tolerogeneic function toward both innate and acquired immune cells. Soluble HLA-G is an immunosuppressive molecule inducing apoptosis of activated CD8(+) T cells and down-modulating CD4(+) T cell proliferation. Recently, using specific ELISA to analyse the presence of sHLA-G molecules in culture supernatants of early embryos obtained by in vitro fertilization (IVF) before transfer, several reports demonstrated that positive embryo implantations occurred with embryo secreting sHLA-G molecules. These breakthrough results indicate that sHLA-G ELISA can be a useful biochemical assay in addition to embryo morphology in embryo selection for transfer in IVF treatment if there are other embryos with the same morphology. Furthermore, monitoring of sHLA-G in amniotic fluid and plasma of pregnant women may have an important prognostic value to recognize pathological situations. Other interesting observations suggest that HLA-G molecules seem to be directly involved in transplant acceptation, and their analysis should be taken into consideration when monitoring transplant-patients status. In addition, soluble HLA-G plasma levels are increased in lyphoproliferative disorders or in patients suffering from malignant melanoma, glioma, breast and ovarian cancer.

Product References (50)

References

  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
  • .
Summary References (20)

References to HLA-G

  • Fujii T., Ishitani A., Geraghty D.E.: A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol. 1994; 153: 5516–5524
  • Le Bouteiller P., Mallet V.: HLA-G and pregnancy. Rev Reprod. 1997; 2: 7–13
  • Blaschitz A., Lenfant F., Mallet V., Hartmann M., Bensussan A., Geraghty D.E., Le Bouteiller P., Dohr G.: Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur Immunol. 1997; 27: 3380–3388
  • Chu W., Fant M.E., Geraghty D.E., Hunt J.S.: Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-gamma-activated macrophages but not placental fibroblasts. Hum Immunol. 1998; 59: 435–442
  • Moreau P., Paul P., Rouas-Freiss N., Kirszenbaum M., Dausset J., Carosella E.D.: Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft. Am J Reprod Immunol. 1998; 40: 136–144
  • Rebman V., Pfeiffer K., Passler M., Ferrone S., Maier S., Weiss E., Grosse-Wilde H.: Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens. 1999; 53: 14–22
  • Hunt J.S., Jadhav L., Chu W., Geraghty D.E., Ober C.: Soluble HLA-G circulates in maternal blood during pregnancy. J Am Obstet Gynecol. 2000; 183: 682–688
  • Emmer P.M., Steegers E.A., van Lierop M.J., Steegers-Theunissen R.P., Loke Y.W., Joosten I.: Amniotic fluid soluble human leukocyte antigen G is markedly decreased in offspring with neural tube defects. Early Hum Dev. 2002; 66: 101–105
  • Fuzzi B., Rizzo R., Criscuoli L., Noci I., Melchiorri L., Scarselli B., Bencini E., Menicucci A., Baricordi O.R.: HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol. 2002; 32: 311–315
  • Lila N., Amrein C., Guillemain R., Chevalier P., Latremouille C., Fabiani J.N., Dausset J., Carosella E.D., Carpentier A.: Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation. 2002; 105: 1949–1954
  • Carosella E.D., Moreau P., Le Maoult J., Le Discorde M., Dausset J., Rouas-Freiss N.: HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol. 2003; 81: 199–252
  • LeMaoult J., Le Discorde M., Rouas-Freiss N., Moreau P., Menier C., McCluskey J., Carosella E.D.: Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens. 2003; 62: 273–284
  • Le Bouteiller P., Legrand-Abravanel F., Solier C.: Soluble HLA-G1 at the materno-foetal interface—a review. Placenta. 2003; 24 Suppl A:S10–5
  • Steinborn A., Rebmann V., Scharf A., Sohn C., Grosse-Wilde H.: Placental abruption is associated with decreased maternal plasma levels of soluble HLA-G. J Clin Immunol. 2003; 23: 307–314
  • Le Bouteiller P., Pizzato N., Barakonyi A., Solier C.: HLA-G, pre-eclampsia, immunity and vascular events. J Reprod Immunol. 2003; 59: 219–234
  • Creput C., Durrbach A., Menier C., Guettier C., Samuel D., Dausset J., Charpentier B., Carosella E.D., Rouas-Freiss N.: Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003; 39: 587–594
  • Sebti Y., Le Friec G., Pangault C., Gros F., Drenou B., Guilloux V., Bernard M., Lamy T., Fauchet R., Amiot L.: Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003; 64: 1093–1101
  • Rebmann V., Regel J., Stolke D., Grosse-Wilde H.: Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003; 13: 371–377 sHLA-G ELISA (page 13 of 16) VERSION: 33 120607 15
  • Sher G., Keskintepe L., Nouriani M., Roussev R., Batzofin J.: Expression of sHLA-G in supernatants of individually cultured 46-h embryos: a potentially valuable indicator of 'embryo competency and IVF outcome. Reprod Biomed Online. 2004; 9: 74–78
  • Noci I., Fuzzi B., Rizzo R., Melchiorri L., Criscuoli L., Dabizzi S., Bi
Related Products Docs
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
zavřít